Retatrutide is the most powerful obesity peptide most people can name — a triple agonist that hit roughly 28% weight loss in Phase 3. At the American Diabetes Association's 2026 Scientific Sessions, a preclinical compound called VRX-0075 quietly did something retatrutide hasn't: it beat it.
VRX-0075 — informally nicknamed "GLP-5" in research-community circles for its five-receptor design — is a long-acting quintuple agonist engineered to activate five receptors at once: GLP-1, GIP, glucagon, amylin, and calcitonin. In obese rats dosed at the same molar level, it produced greater weight loss than retatrutide. That result, late-breaking poster 2839-LB, is the news. (The "GLP-5" label is a colloquial shorthand, not an official drug class — there is no receptor called GLP-5.)
The important caveat lives in one word: rats. This is animal data with no human trial behind it. Here is what it actually shows, and what it means for retatrutide research today.
Research-context information only. Compounds discussed below are research peptides and supplements; some are investigational drugs not approved by the FDA. Protocols, doses, and reactions reported come from published research and self-reported community sources. Possession or use of investigational drugs outside an authorized clinical trial may be illegal in your jurisdiction. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
What the ADA 2026 Data Showed
The poster, identified as abstract 2839-LB, describes VRX-0075 as a long-acting agonist built to hit five receptor pathways in a single molecule. The headline finding: in a diet-induced obese rat model, VRX-0075 induced greater weight loss than retatrutide at the same molar dose.
The receptor design is the whole story. VRX-0075's reported in-vitro potency is comparable to retatrutide at the three incretin-axis receptors — GLP-1, GIP, and glucagon — while matching cagrilintide's potency at the amylin and calcitonin receptors. In other words, it bolts the entire amylin/satiety mechanism onto a retatrutide-style backbone.
The abstract also reported a half-life roughly 50% longer than semaglutide, which the authors framed as supporting once-weekly dosing if the molecule advances to humans. No human dosing, safety, tolerability, or efficacy data was presented — this is a preclinical readout only.
For context on how far the field has pushed weight loss numbers through receptor stacking: semaglutide (one receptor) reached ~15%, tirzepatide (two) ~22.5%, and retatrutide (three) ~28.7% in their respective trials. The quintuple-agonist bet is that adding the amylin and calcitonin axis on top can push efficacy further still — toward the >30% territory that, until now, mostly belonged to bariatric surgery.
Why the Amylin Axis Is the New Frontier
Every leap in obesity-drug efficacy has come from adding an independent mechanism. The first three additions — GLP-1, GIP, glucagon — are the incretin and glucagon axis. The fourth and fifth, amylin and calcitonin, are a different system entirely: the satiety and gastric-emptying axis that pramlintide pioneered and that cagrilintide and eloralintide revived.
That matters because mechanisms that don't overlap tend to add rather than blunt each other. Amylin slows gastric emptying and signals fullness to the hindbrain through pathways largely separate from GLP-1. Eloralintide data showed amylin alone could reach ~20% weight loss in Phase 2 — see our eloralintide Phase 2 breakdown. Cagrilintide does the same job and is already accessible. VRX-0075 simply fuses both halves — incretin axis plus amylin axis — into one weekly shot.
This is the same logic behind every dual-mechanism stack research-vendor buyers already run: pair a GLP-1/GIP/glucagon agent with an amylin agent. The quintuple agonist is the pharma industry trying to do in one molecule what self-experimenters do with two vials.
This section includes affiliate links; The Peptide Catalog may earn a commission on purchases.
What This Means for Peptide Buyers Today
VRX-0075 is not for sale. It is a preclinical compound with no human data, no manufacturer-confirmed clinical timeline, and no presence in any research-peptide catalog. Any vendor claiming to sell "VRX-0075" or a "quintuple agonist" is selling a fraudulent product — the molecule does not exist outside a lab.
What you can buy today are the building blocks the quintuple agonist is assembled from:
- Retatrutide covers three of the five targets (GLP-1, GIP, glucagon) and is the closest accessible analog to VRX-0075's incretin backbone. Research-grade availability is stable as Phase 3 TRIUMPH data continues to accumulate, with analyst timelines pointing toward a possible 2027 NDA submission window. Compare retatrutide vendors for current pricing and COA-verified options, and see the retatrutide dosing guide for protocol details.
- Cagrilintide covers the amylin and calcitonin side — the exact two receptors VRX-0075 adds on top of retatrutide. It is the only widely stocked amylin analog and stacks cleanly with GLP-1 agents. Compare cagrilintide vendors, with background in the cagrilintide dosing guide.
- Tirzepatide and semaglutide remain the most accessible incretin options if retatrutide's glucagon arm isn't a priority. See tirzepatide buying options and semaglutide vendor comparison.
Community sources describe running retatrutide alongside cagrilintide as the closest available approximation of VRX-0075's five-pathway coverage — see the retatrutide + cagrilintide stack guide for how that pairing is structured.
